These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28679020)

  • 1. A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies.
    Zhang L; Peters G; Haskell L; Patel P; Nandy P; Moore KT
    J Clin Pharmacol; 2017 Dec; 57(12):1607-1615. PubMed ID: 28679020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of men and meals.
    Beyer-Westendorf J; Siegert G
    J Thromb Haemost; 2015 Jun; 13(6):943-5. PubMed ID: 25880707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
    Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
    J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.
    Dias C; Moore KT; Murphy J; Ariyawansa J; Smith W; Mills RM; Weir MR
    Am J Nephrol; 2016; 43(4):229-36. PubMed ID: 27100875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients.
    Konicki R; Weiner D; Herbert Patterson J; Gonzalez D; Kashuba A; Cao YC; Gehi AK; Watkins P; Powell JR
    Clin Transl Sci; 2020 Jul; 13(4):777-784. PubMed ID: 32267996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube.
    Moore KT; Krook MA; Vaidyanathan S; Sarich TC; Damaraju CV; Fields LE
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):321-7. PubMed ID: 27128839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ; Amerena JV
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs.
    Lynch AM; Ruterbories LK; Griffith E; Hanel RM; Stablein AP; Brooks MB
    J Vet Emerg Crit Care (San Antonio); 2021 Jan; 31(1):59-65. PubMed ID: 33107158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).
    Lip GY; Hammerstingl C; Marin F; Cappato R; Meng IL; Kirsch B; Morandi E; van Eickels M; Cohen A
    Am Heart J; 2015 Apr; 169(4):464-71.e2. PubMed ID: 25819852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
    Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects.
    Brunner-Ziegler S; Jilma B; Schörgenhofer C; Winkler F; Jilma-Stohlawetz P; Koppensteiner R; Quehenberger P; Seger C; Weigel G; Griesmacher A; Brunner M
    J Thromb Haemost; 2016 Feb; 14(2):316-23. PubMed ID: 26644369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
    Greenblatt DJ; Patel M; Harmatz JS; Nicholson WT; Rubino CM; Chow CR
    J Clin Pharmacol; 2018 Apr; 58(4):533-540. PubMed ID: 29194698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
    Siegmund HU; Burghaus R; Kubitza D; Coboeken K
    Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dosing of rivaroxaban is undefined.
    Moore TJ
    BMJ; 2016 Oct; 355():i5549. PubMed ID: 27756735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.